XML 56 R44.htm IDEA: XBRL DOCUMENT v2.4.0.8
Business Combinations (SARcode, Premacure and Lotus) (Details) (USD $)
In Millions, unless otherwise specified
3 Months Ended 9 Months Ended 9 Months Ended 9 Months Ended
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Sep. 30, 2012
Sep. 30, 2013
Lotus
Sep. 30, 2012
Lotus
Feb. 12, 2013
Lotus
Feb. 12, 2013
Lotus
purchase price allocation
Sep. 30, 2013
SARcode Biosciences Inc
Sep. 30, 2012
SARcode Biosciences Inc
Apr. 17, 2013
SARcode Biosciences Inc
Apr. 17, 2013
SARcode Biosciences Inc
purchase price allocation
Sep. 30, 2013
Premacure AB
Sep. 30, 2012
Premacure AB
Mar. 08, 2013
Premacure AB
Mar. 08, 2013
Premacure AB
purchase price allocation
Business Acquisition [Line Items]                                
Percentage of voting interests acquired             100.00%       100.00%       100.00%  
Cash consideration paid             $ 49.4       $ 151.0       $ 30.6  
Maximum amount of contingent cash consideration             275.0       525.0       169.0  
Integration and acquisition costs 18.4 2.7 39.9 15.1 4.6 0     14.7 0     9.8 0    
Acquisition-date fair value of consideration totaled             174.2       368.0       140.2  
Fair value of contingent consideration payable             124.8       217.0       109.6  
Net current assets assumed               6.8                
Goodwill         54.1     54.1 86.6     86.6       29.6
Net non-current liabilities assumed (including deferred tax liabilities)               63.4       122.4       29.5
Post acquisition pre-tax losses included in consolidated statement of income                 17.4 0            
IPR&D               176.7       412.0       151.8
Net current liabilities assumed                       $ 8.2       $ 11.7